Cost Effectiveness of Denosumab for Secondary Prevention of Osteoporotic Fractures Among Postmenopausal Women in China: An Individual-Level Simulation Analysis

[1]  Takahiro Mori,et al.  Cost-Effectiveness of Sequential Denosumab/Zoledronic Acid Compared With Zoledronic Acid Monotherapy for Postmenopausal Osteoporotic Women in China , 2022, Frontiers in Pharmacology.

[2]  E. Winter,et al.  The effect of osteoporosis treatment on bone mass. , 2022, Best practice & research. Clinical endocrinology & metabolism.

[3]  M. Drummond,et al.  Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: Updated reporting guidance for health economic evaluations , 2022, BMJ.

[4]  Yu Zhang,et al.  Which injected antiosteoporotic medication is worth paying for? A cost-effectiveness analysis of teriparatide, zoledronate, ibandronate, and denosumab for postmenopausal osteoporotic women in China. , 2021, Menopause.

[5]  J. Sahhar,et al.  Screening rates and prevalence of osteoporosis in a real‐world, Australian systemic sclerosis cohort , 2021, International journal of rheumatic diseases.

[6]  Yawen Jiang,et al.  Estimation of the cost-effective threshold of a quality-adjusted life year in China based on the value of statistical life , 2021, The European Journal of Health Economics.

[7]  C. Critchlow,et al.  A Novel Case Study of the Use of Real-World Evidence to Support the Registration of an Osteoporosis Product in China , 2021, Therapeutic Innovation & Regulatory Science.

[8]  E. Boschitsch,et al.  Long-term persistence with denosumab: real-world data from the Austrian Osteoporosis Clinic (AOC). A retrospective data analysis , 2021, Osteoporosis International.

[9]  S. Cummings,et al.  Prevalence of Osteoporosis and Fracture in China , 2021, JAMA network open.

[10]  C. Crandall,et al.  Cost-effectiveness of zoledronic acid compared with sequential denosumab/alendronate for older osteoporotic women in Japan , 2021, Archives of Osteoporosis.

[11]  A. Burden,et al.  Duration of Bisphosphonate Drug Holidays in Osteoporosis Patients: A Narrative Review of the Evidence and Considerations for Decision-Making , 2021, Journal of clinical medicine.

[12]  Louise B. Russell,et al.  Estimating Transition Probabilities from Published Evidence: A Tutorial for Decision Modelers , 2020, PharmacoEconomics.

[13]  N. Watts,et al.  AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS/AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS-2020 UPDATE. , 2020, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[14]  G. Toro,et al.  Pharmacological Therapy of Osteoporosis: What’s New? , 2020, Clinical interventions in aging.

[15]  G. Chodick,et al.  Fracture incidence after denosumab discontinuation: Real-world data from a large healthcare provider. , 2019, Bone.

[16]  Jing Wu,et al.  Healthcare Resource Utilization and Direct Medical Costs for Patients With Osteoporotic Fractures in China. , 2019, Value in health regional issues.

[17]  H. Sørensen,et al.  Comparison of Risk of Osteoporotic Fracture in Denosumab vs Alendronate Treatment Within 3 Years of Initiation , 2019, JAMA network open.

[18]  I. Venkatachalam,et al.  Efficacy and safety of denosumab compared to bisphosphonates in improving bone strength in postmenopausal osteoporosis: a systematic review. , 2019, Singapore medical journal.

[19]  I. Okubo,et al.  Cost-effectiveness analysis of drugs for osteoporosis treatment in elderly Japanese women at high risk of fragility fractures: comparison of denosumab and weekly alendronate , 2018, Archives of Osteoporosis.

[20]  Jacques P. Brown,et al.  Vertebral Fractures After Discontinuation of Denosumab: A Post Hoc Analysis of the Randomized Placebo‐Controlled FREEDOM Trial and Its Extension , 2018, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[21]  C. Cooper,et al.  European guidance for the diagnosis and management of osteoporosis in postmenopausal women , 2018, Osteoporosis International.

[22]  A. Palmer,et al.  Establishing benchmark EQ-5D-3L population health state utilities and identifying their correlates in Gansu Province, China , 2017, Quality of Life Research.

[23]  C. Crandall,et al.  Cost-effectiveness of denosumab versus oral alendronate for elderly osteoporotic women in Japan , 2017, Osteoporosis International.

[24]  Y. Jiang,et al.  Evaluation on the cost-effective threshold of osteoporosis treatment on elderly women in China using discrete event simulation model , 2017, Osteoporosis International.

[25]  Jörgen Möller,et al.  Advantages and disadvantages of discrete-event simulation for health economic analyses , 2016, Expert review of pharmacoeconomics & outcomes research.

[26]  Yawen Jiang,et al.  Expected lifetime numbers, risks, and burden of osteoporotic fractures for 50-year old Chinese women: a discrete event simulation incorporating FRAX , 2016, Journal of Bone and Mineral Metabolism.

[27]  Jonathan Karnon,et al.  Discrete Event Simulation for Health Technology Assessment , 2015 .

[28]  A. Palmer,et al.  Residual lifetime and 10 year absolute risks of osteoporotic fractures in Chinese men and women , 2015, Current medical research and opinion.

[29]  C. Becker,et al.  Expected lifetime numbers and costs of fractures in postmenopausal women with and without osteoporosis in Germany: a discrete event simulation model , 2014, BMC Health Services Research.

[30]  A. Palmer,et al.  A systematic review of models used in cost-effectiveness analyses of preventing osteoporotic fractures , 2013, Osteoporosis International.

[31]  N. Freemantle,et al.  Results of indirect and mixed treatment comparison of fracture efficacy for osteoporosis treatments: a meta-analysis , 2012, Osteoporosis International.

[32]  J. Caro,et al.  Pharmacoeconomic analyses using discrete event simulation , 2012, PharmacoEconomics.

[33]  J. Cauley,et al.  Ethnic difference of clinical vertebral fracture risk , 2011, Osteoporosis International.

[34]  B. Ettinger,et al.  Updated fracture incidence rates for the US version of FRAX® , 2009, Osteoporosis International.

[35]  J. Eisman,et al.  Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. , 2009, JAMA.

[36]  L. Ning.  Statistics on the Expenses for Medical Care of Osteoporotic Fractures in Beijing Jishuitan Hospital(from 2000 to 2006) , 2009 .

[37]  中華人民共和国国家統計局.  中华人民共和国国民经济和社会发展统计公报 = Statistical communique of The People's Republic of China on the national economic and social development , 2008 .

[38]  A. Ho,et al.  Ten‐Year Risk of Osteoporotic Fractures in Postmenopausal Chinese Women According to Clinical Risk Factors and BMD T‐Scores: A Prospective Study , 2007, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[39]  Sadao Suzuki,et al.  Risk of mortality following hip fracture in Japan , 2007, Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association.

[40]  J. Eisman,et al.  Risk of subsequent fracture after low-trauma fracture in men and women. , 2007, JAMA.

[41]  B. Ettinger,et al.  Persistence with weekly alendronate therapy among postmenopausal women , 2006, Osteoporosis International.

[42]  O. Johnell,et al.  The components of excess mortality after hip fracture. , 2003, Bone.

[43]  S. Papapoulos,et al.  A New Approach to the Development of Assessment Guidelines for Osteoporosis , 2002, Osteoporosis International.

[44]  J. Kanis,et al.  Diagnosis of osteoporosis and assessment of fracture risk , 2002, The Lancet.

[45]  S. Cummings,et al.  Epidemiology and outcomes of osteoporotic fractures , 2002, The Lancet.

[46]  Osteoporosis: review of the evidence for prevention, diagnosis and treatment and cost-effectiveness analysis. Introduction. , 1998, Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA.